Semaglutide is a long-acting GLP-1 receptor agonist that increases glucose-dependent insulin secretion decreases inappropriate glucagon secretion, slows gastric emptying; also acts in the areas of the brain involved in the regulation of appetite and caloric intake.
Contraindications: Family or personal history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type II, Type 1 diabetes, breastfeeding, or hypersensitivity.